サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1317791

ドキソルビシン市場：剤形、流通チャネル、用途別-2023-2030年の世界予測

Doxorubicin Market by Drug Formulation, Distribution Channel, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ドキソルビシン市場：剤形、流通チャネル、用途別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ドキソルビシンの世界市場は、2023年にCAGR 10.80%で23億9,759万米ドルと予測され、2030年には49億2,193万米ドルと驚異的な成長を遂げると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のドキソルビシン市場を評価するために不可欠です。事業戦略および製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.ドキソルビシンの世界市場規模および予測は？

2.予測期間中、世界のドキソルビシン市場を形成するCOVID-19の阻害要因と影響は？

3.ドキソルビシンの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.ドキソルビシンの世界市場における競争戦略は？

5.ドキソルビシンの世界市場における技術動向と規制の枠組みは？

6.ドキソルビシンの世界市場における主要ベンダーの市場シェアは？

7.ドキソルビシンの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中でガンの罹患率が増加
      • 特定の疾患に対するドキソルビシンの使用に対する政府の承認
      • 認識と医薬品の入手可能性を高めるための取り組みの拡大
    • 抑制要因
      • 規制の枠組みの変化
    • 機会
      • 新規創薬・開発に向けた研究開発を継続中
      • がんの治療と予防に対する政府の支援的取り組み
    • 課題
      • 薬の重大な副作用
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 ドキソルビシン市場製剤別

  • ドキソルビシンインジェクション
  • 凍結乾燥粉末

第7章 ドキソルビシン市場：流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第8章 ドキソルビシン市場：用途別

  • 骨肉腫
  • 乳がん
  • 子宮内膜がん
  • 胃がん
  • カポジ肉腫
  • 腎臓がん
  • 白血病
  • 肝臓がん
  • 多発性骨髄腫
  • 卵巣がん

第9章 南北アメリカのドキソルビシン市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のドキソルビシン市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのドキソルビシン市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. DOXORUBICIN MARKET RESEARCH PROCESS
  • FIGURE 2. DOXORUBICIN MARKET SIZE, 2022 VS 2030
  • FIGURE 3. DOXORUBICIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2022 VS 2030 (%)
  • FIGURE 5. DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 6. DOXORUBICIN MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 7. DOXORUBICIN MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. DOXORUBICIN MARKET DYNAMICS
  • FIGURE 9. DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. DOXORUBICIN MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. DOXORUBICIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. DOXORUBICIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 5. DOXORUBICIN MARKET SIZE, BY DOXORUBICIN INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. DOXORUBICIN MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 8. DOXORUBICIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. DOXORUBICIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. DOXORUBICIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. DOXORUBICIN MARKET SIZE, BY BONE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. DOXORUBICIN MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. DOXORUBICIN MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. DOXORUBICIN MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. DOXORUBICIN MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. DOXORUBICIN MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. DOXORUBICIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. DOXORUBICIN MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. DOXORUBICIN MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. DOXORUBICIN MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 150. DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 151. DOXORUBICIN MARKET LICENSE & PRICING
目次
Product Code: MRR-ED54C46E8678

The Global Doxorubicin Market is forecasted to grow significantly, with a projected USD 2,397.59 million in 2023 at a CAGR of 10.80% and expected to reach a staggering USD 4,921.93 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Doxorubicin Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Doxorubicin Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Formulation, market is studied across Doxorubicin Injection and Lyophilized Powder. The Doxorubicin Injection is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Online Pharmacy is projected to witness significant market share during forecast period.

Based on Application, market is studied across Bone Sarcoma, Breast Cancer, Endometrial Cancer, Gastric Cancer, Kaposi Sarcoma, Kidney Cancer, Leukemia, Liver Cancer, Multiple Myeloma, and Ovarian Cancer. The Liver Cancer is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Doxorubicin Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Doxorubicin Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Doxorubicin Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Doxorubicin Market?

4. What is the competitive strategic window for opportunities in the Global Doxorubicin Market?

5. What are the technology trends and regulatory frameworks in the Global Doxorubicin Market?

6. What is the market share of the leading vendors in the Global Doxorubicin Market?

7. What modes and strategic moves are considered suitable for entering the Global Doxorubicin Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Doxorubicin Market, by Drug Formulation, 2022 vs 2030
  • 4.3. Doxorubicin Market, by Distribution Channel, 2022 vs 2030
  • 4.4. Doxorubicin Market, by Application, 2022 vs 2030
  • 4.5. Doxorubicin Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing cancer incidence rate worldwide
      • 5.1.1.2. Government approvals for use of doxorubicin against certain disorders
      • 5.1.1.3. Growing effort towards increasing awareness and drug availability
    • 5.1.2. Restraints
      • 5.1.2.1. Changing regulatory frameworks
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for novel drug discovery and development
      • 5.1.3.2. Supportive government initiatives for cancer treatment and prevention
    • 5.1.4. Challenges
      • 5.1.4.1. Serious side effects of the drug
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Doxorubicin Market, by Drug Formulation

  • 6.1. Introduction
  • 6.2. Doxorubicin Injection
  • 6.3. Lyophilized Powder

7. Doxorubicin Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Online Pharmacy
  • 7.4. Retail Pharmacy

8. Doxorubicin Market, by Application

  • 8.1. Introduction
  • 8.2. Bone Sarcoma
  • 8.3. Breast Cancer
  • 8.4. Endometrial Cancer
  • 8.5. Gastric Cancer
  • 8.6. Kaposi Sarcoma
  • 8.7. Kidney Cancer
  • 8.8. Leukemia
  • 8.9. Liver Cancer
  • 8.10. Multiple Myeloma
  • 8.11. Ovarian Cancer

9. Americas Doxorubicin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Doxorubicin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Doxorubicin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing